Patents Assigned to Gilead Sciences, Inc.
  • Pharmaceutical formulations comprising tenofovir alafenamide and emtricitabine
    Patent number: 12678408
    Abstract: The invention provides a solid oral dosage form comprising tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: February 20, 2026
    Date of Patent: July 14, 2026
    Assignee: Gilead Sciences, Inc.
    Inventors: Joanna M. Koziara, Scott McCallister
  • Pharmaceutical formulations comprising tenofovir alafenamide and emtricitabine
    Patent number: 12661323
    Abstract: The invention provides a solid oral dosage form comprising tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: January 27, 2026
    Date of Patent: June 23, 2026
    Assignee: Gilead Sciences, Inc.
    Inventors: Joanna M. Koziara, Scott McCallister
  • Solid forms of a nucleoside analogue and uses thereof
    Patent number: 12655172
    Abstract: The present disclosure relates to solid forms (e.g. crystalline forms, solvates, and crystalline forms thereof) of a compound which is ((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methyl neopentyl carbonate, which is useful in the treatment of treating viral infections, for example paramyxoviridae, pneumoviridae, picornaviridae, flaviviridae, filoviridae, arenaviridae, orthomyxovirus, and coronaviridae infections.
    Type: Grant
    Filed: June 29, 2023
    Date of Patent: June 16, 2026
    Assignee: Gilead Sciences, Inc.
    Inventors: Kassibla E. Dempah, Chiajen Lai
  • Pharmaceutical formulations comprising tenofovir alafenamide and emtricitabine
    Patent number: 12648911
    Abstract: The invention provides a solid oral dosage form comprising tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: January 30, 2026
    Date of Patent: June 9, 2026
    Assignee: Gilead Sciences, Inc.
    Inventors: Joanna M. Koziara, Scott McCallister
  • Choline salt forms of an HIV capsid inhibitor
    Patent number: 12636279
    Abstract: The present disclosure relates to choline salts, and crystalline forms thereof, of a compound which is N—((S)-1-(3-(4-chloro-3-(methylsulfonamido)-1-(2,2,2-trifluoroethyl)-1H-indazol-7-yl)-6-(3-methyl-3-(methylsulfonyl)but-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-5,5-difluoro-3- (trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide, which is useful in the treatment and prevention of a Retroviridae viral infection including an infection caused by the HIV virus.
    Type: Grant
    Filed: October 24, 2023
    Date of Patent: May 26, 2026
    Assignee: Gilead Sciences, Inc.
    Inventors: Travis Lee Houston, Bing Shi
  • Pharmaceutical formulations comprising tenofovir alafenamide and emtricitabine
    Patent number: 12629338
    Abstract: The invention provides a solid oral dosage form comprising tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: January 16, 2026
    Date of Patent: May 19, 2026
    Assignee: Gilead Sciences, Inc.
    Inventors: Joanna M. Koziara, Scott McCallister
  • Method of inducing an HIV-1-specific immune response using a chimpanzee adenovirus vector encoding an hivacat t-cell immunogen and TLR7 agonist
    Patent number: 12611453
    Abstract: The present disclosure describes methods, compositions, and kits related to the combination of a TLR7 modulating compound and an HIV vaccine. The combination can be used in a method of treating or preventing an HIV infection in a human.
    Type: Grant
    Filed: May 21, 2020
    Date of Patent: April 28, 2026
    Assignee: Gilead Sciences, Inc.
    Inventors: Romas Geleziunas, Devi Sengupta, Christian Brander, Beatriz Mothe Pujadas, Ian McGowan
  • Therapeutic compositions for treatment of human immunodeficiency virus
    Patent number: 12594244
    Abstract: A solid oral dosage form is provided, comprising a compound of Formula I or a pharmaceutically acceptable salt thereof, tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 29, 2025
    Date of Patent: April 7, 2026
    Assignee: Gilead Sciences, Inc.
    Inventors: Benjamin Micah Collman, Lei Hong, Joanna M. Koziara
  • Capsid inhibitors for the treatment of HIV
    Patent number: 12594267
    Abstract: The present disclosure relates to compounds of Formula (Ia) and (Ib): or a pharmaceutically acceptable salt thereof, which are useful in the treatment of an HIV infection in heavily treatment-experienced patients with multidrug resistant HIV infection.
    Type: Grant
    Filed: February 27, 2024
    Date of Patent: April 7, 2026
    Assignee: Gilead Sciences, Inc.
    Inventors: Anna Chiu, Charles William Rowe, Scott P. Sellers
  • Processes for preparing toll-like receptor modulator compounds
    Patent number: 12590089
    Abstract: The present disclosure provides methods for preparing (R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhexan-1-ol or a salt thereof and related key intermediates.
    Type: Grant
    Filed: February 16, 2022
    Date of Patent: March 31, 2026
    Assignee: Gilead Sciences, Inc.
    Inventors: Andrea Ambrosi, Florence J. Bachrach, Pavel R. Badalov, Stephen P. Lathrop, Jeffrey E. Merit, Beau P. Pritchett, Christopher S. Regens, Tiago Vieira, Adam B. Weinstein, Todd A. Wenderski, Zehua Zheng
  • PD-1/PD-L1 inhibitors
    Patent number: 12590062
    Abstract: Compounds according to formula (I), methods of using said compounds singly or in combination with additional agents and compositions of said compounds for the treatment of cancer are disclosed.
    Type: Grant
    Filed: November 13, 2020
    Date of Patent: March 31, 2026
    Assignee: Gilead Sciences, Inc.
    Inventors: Evangelos Aktoudianakis, Todd Appleby, Aesop Cho, Zhimin Du, Michael Graupe, Juan A. Guerrero, Salman Y. Jabri, Lateshkumar Thakorlal Lad, Paulo A. Machicao Tello, Jonathan William Medley, Samuel E. Metobo, Prasenjit Kumar Mukherjee, Devan Naduthambi, Gregory Notte, Eric Q. Parkhill, Barton W. Phillips, Scott Preston Simonovich, Neil H. Squires, Chandrasekar Venkataramani, Peiyuan Wang, William J. Watkins, Jie Xu, Kin Shing Yang, Christopher Allen Ziebenhaus
  • GLP-IR modulating compounds
    Patent number: 12570642
    Abstract: The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.
    Type: Grant
    Filed: October 27, 2023
    Date of Patent: March 10, 2026
    Assignee: Gilead Sciences, Inc.
    Inventors: Megan K. Armstrong, James S. Cassidy, Elbert Chin, Chienhung Chou, Jeromy J. Cottell, Chao-I Hung, Kavoos Kolahdouzan, David W. Lin, Michael L. Mitchell, Ezra Roberts, Scott D. Schroeder, Nathan D. Shapiro, James G. Taylor, Rhiannon Thomas-Tran, Nathan E. Wright, Zheng-Yu Yang
  • Substituted pyrrolo[1,2-b]pyridazines as bifunctional degraders of interleukin-1 receptor-associated kinases
    Patent number: 12570662
    Abstract: The present disclosure provides bifunctional compounds represented by Formula (I) as IRAK4 degraders via ubiquitin proteasome pathway, and methods for treating diseases modulated by IRAK4:
    Type: Grant
    Filed: April 1, 2024
    Date of Patent: March 10, 2026
    Assignees: Nurix Therapeutics, Inc., Gilead Sciences, Inc.
    Inventors: Wylie Palmer, Jeffrey Wu, John Lee, Kerem Ozboya, Tim Kane
  • Methods of identifying HIV patients sensitive to therapy with gp120 CD4 binding site-directed antibodies
    Patent number: 12559546
    Abstract: Provided are methods for identifying patient populations infected with HIV that can be targeted by antibodies that bind to HIV gp120 CD4 binding site (CD4bs) region.
    Type: Grant
    Filed: November 9, 2021
    Date of Patent: February 24, 2026
    Assignee: Gilead Sciences, Inc.
    Inventors: Stephen R. Martin, Brian Moldt, Aiyappa Parvangada
  • IL-31 modulators for treating FXR-induced pruritus
    Patent number: 12559553
    Abstract: The present disclosure relates generally to methods of using modulators of interleukin-31 (IL-31) for treating, stabilizing, or lessening the severity or progression of pruritis.
    Type: Grant
    Filed: June 17, 2022
    Date of Patent: February 24, 2026
    Assignee: Gilead Sciences, Inc.
    Inventors: Andrew Nicholas Billin, Jun Xu
  • Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof
    Patent number: 12528814
    Abstract: The present disclosure provides bifunctional compounds as IRAK4 degraders via ubiquitin proteasome pathway, and method for treating diseases modulated by IRAK4.
    Type: Grant
    Filed: February 19, 2021
    Date of Patent: January 20, 2026
    Assignees: Nurix Therapeutics, Inc., Gilead Sciences, Inc.
    Inventors: Wylie Solang Palmer, Jeffrey Wu, Sheila Zipfel, Kerem Ozboya, Dahlia Weiss
  • Antiviral indolinyl compounds and uses thereof
    Patent number: 12522582
    Abstract: The present disclosure relates to indolinyl compounds. The present disclosure further relates to compounds that inhibit viral helicase-primase. The present disclosure further relates to the use of the compounds for the preparation a medicament for the treatment of diseases and/or condition through inhibiting viral helicase-primase. The present disclosure also relates to use of those compounds in the treatment of viral infections. The present disclosure further relates to intermediates for its preparation and to pharmaceutical compositions containing those compounds.
    Type: Grant
    Filed: May 18, 2023
    Date of Patent: January 13, 2026
    Assignee: Gilead Sciences, Inc.
    Inventors: Aesop Cho, Katherine De La Fuente, Thomas P. Stratton, Peiyuan Wang, William J. Watkins, Jie Xu, Kin S. Yang
  • Toll like receptor modulator compounds
    Patent number: 12522570
    Abstract: This application relates generally to toll like receptor modulator compounds and pharmaceutical compositions which, among other things, modulate toll-like receptors (e.g. TLR8), and methods of making and using them.
    Type: Grant
    Filed: September 27, 2023
    Date of Patent: January 13, 2026
    Assignee: Gilead Sciences, Inc.
    Inventors: Gregory Chin, Richard L. Mackman, Michael R. Mish, Jeff Zablocki
  • Blister pack
    Patent number: D1118367
    Type: Grant
    Filed: September 23, 2025
    Date of Patent: March 17, 2026
    Assignee: Gilead Sciences, Inc.
    Inventors: Robert Bridges, Joseph Cordova, Gaurav Dabholkar, Alexandra Fideler, Monica Vazirani
  • Pharmaceutical package
    Patent number: D1131202
    Type: Grant
    Filed: January 29, 2024
    Date of Patent: June 23, 2026
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Benjamin Luke Kozub, Brian Nilstoft, Kevin Nguyen, James Paul Oberhauser, Roman Shumylo, Joseph Anthony Cordova, Jinhui Yun, William Harold Lizor, Jr., Adam Hilborn, Jesse Arnold Fourt, Léo Boris Marzolf, Pratap Uday Ganapathy, Brooke Genelle Thyng, Caricia Catalani, Soizic Porhel, Jose Angel Meza, Steven M. Scally, Mary Cassandra Lodwick